This is a blood letting at this point. The passed
Post# of 153880
(Total Views: 649)
Posted On: 05/28/2020 10:41:55 AM
This is a blood letting at this point. The passed two days of declines should give some insight into how poorly planned and managed that cc was. If they don't have something of actual substance to share, then they shouldn't be holding a cc.
Their product is great but their execution is abysmal, as stated before. If Cytodyn has another two days of this same pattern, they will have no choice but to go for the interim data release in order to buoy the share price. Even a slightly dilutive fundraising announcement can be a absolute disaster right now. They need to produce some results to move the share price up any further. I really hope they have some positive insight coming from the UK or Mexico tomorrow. If not, I expect we will see the same exact pattern.
It seems that the demand for the stock is there, but it appears that most investors are not inclined to pay anything north of $3.00 without empirical data being published. Everyday we move forward without data, we risk losing further market value. We are maxed out with speculation. Time to produce results.
I rarely hold in this situation however, I am convinced that Cytodyn has some extremely sunny days ahead. I will NOT increase my position, as I am satisfied with where I stand given the timelines set forth my management. Any increase in position at this juncture must depend on the data release and any impact that data carries with it.
Their product is great but their execution is abysmal, as stated before. If Cytodyn has another two days of this same pattern, they will have no choice but to go for the interim data release in order to buoy the share price. Even a slightly dilutive fundraising announcement can be a absolute disaster right now. They need to produce some results to move the share price up any further. I really hope they have some positive insight coming from the UK or Mexico tomorrow. If not, I expect we will see the same exact pattern.
It seems that the demand for the stock is there, but it appears that most investors are not inclined to pay anything north of $3.00 without empirical data being published. Everyday we move forward without data, we risk losing further market value. We are maxed out with speculation. Time to produce results.
I rarely hold in this situation however, I am convinced that Cytodyn has some extremely sunny days ahead. I will NOT increase my position, as I am satisfied with where I stand given the timelines set forth my management. Any increase in position at this juncture must depend on the data release and any impact that data carries with it.
(7)
(2)